Commonwealth Equity Services
SABS icon

Commonwealth Equity Services’s SAB Biotherapeutics SABS Stock Holding History

Commonwealth Equity Services’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,455
Closed -$178K – 4547
2026
Q1 		$178K Buy
+46,455
New +$185K ﹤0.01% 4037
2024
Q1 		– Sell
-1,282
Closed -$9K – 4085
2023
Q4 		$9K Buy
+1,282
New +$10.7K ﹤0.01% 3869

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Commonwealth Equity Services's SABS Position: Q2 2026 in Review

Commonwealth Equity Services sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 46,455 shares — an estimated $178K sold.

Commonwealth Equity Services first reported a position in SABS in Q4 2023 and held it in 2 quarters. The position peaked at $178K in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Commonwealth Equity Services reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Commonwealth Equity Services sold 46,455 SAB Biotherapeutics shares in Q2 2026, an estimated $178K.
  • Commonwealth Equity Services first reported a position in SAB Biotherapeutics in Q4 2023 and held it in 2 quarters.
  • Commonwealth Equity Services's SAB Biotherapeutics position peaked at $178K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.